Involving Production Or Treatment Of Antibody Patents (Class 436/547)
-
Patent number: 7476551Abstract: The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and/or deposition of carbamylated LDL in said individual.Type: GrantFiled: August 27, 2002Date of Patent: January 13, 2009Assignee: The Board of Trustees of the University of ArkansasInventors: Yousri M. Barri, Sudhir V. Shah, Alexei G. Basnakian
-
Patent number: 7473564Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.Type: GrantFiled: November 8, 2001Date of Patent: January 6, 2009Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche MedicaleInventors: Philipp Lassalle, David Bechard, André-Bernard Tonnel
-
Patent number: 7452676Abstract: The present invention includes antibodies to human GW182 protein and the use of those antibodies in clinical and diagnostic assays.Type: GrantFiled: January 16, 2004Date of Patent: November 18, 2008Assignee: UTI Limited PartnershipInventor: Marvin J. Fritzler
-
Publication number: 20080274463Abstract: Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry.Type: ApplicationFiled: May 4, 2007Publication date: November 6, 2008Inventors: Xiao-Bo Chen, Christopher Bieniarz, Michael Farrell
-
Publication number: 20080268477Abstract: The present invention provides antibodies against AGEs derived from carbonyl compounds that are highly reactive with proteins or peptides, and methods of detecting the AGEs derived from the carbonyl compounds. 3,4-dideoxyglucosone-3-ene (3,4-DGE) is allowed to react with proteins, a host animal is immunized with the reaction product thereof, AGEs, and antibodies against the AGEs (anti-AGE antibodies) are isolated from serum recovered from the host animal. These anti-AGE antibodies thus isolated are allowed to react with a sample, and then the antigen-antibody reaction between the AGEs in the sample and the anti-AGE antibodies is detected. Thereby the presence or amount of the AGEs in the sample can be detected.Type: ApplicationFiled: March 31, 2006Publication date: October 30, 2008Applicant: JMS CO., LTD.Inventors: Takashi Yamamoto, Yuko Kimura
-
Patent number: 7442516Abstract: The present invention provides an antibody which specifically recognizes a CNS tau protein but not a peripheral tau protein. More specifically, the present invention provides an antibody obtainable by using a polypeptide comprising an amino acid sequence of a connective portion between the amino acid sequence encoded by Exon 4 of a gene encoding a tau protein and the amino acid sequence encoded by Exon 5 thereof as an epitope specific to the isoform of tau protein predominantly existing in central nervous tissues. The present invention further provides a method of detecting Alzheimer's disease and a reagent kit using the antibody.Type: GrantFiled: February 11, 2005Date of Patent: October 28, 2008Assignees: Mitsubishi Chemical Corporation, Mitsubishi Kagaku Iatron, Inc.Inventors: Hideto Ohno, Koichi Ishiguro, Masaki Imagawa
-
Patent number: 7439025Abstract: Antibodies are described, which are suitable for identification of ?-carboxyglutamic acid (Gla), said antibodies having an ability of identifying Gla residues in proteins and/or peptides, while not reacting with glutamic (Glu) residues in corresponding proteins and/or peptides. Methods for the preparation and identification of said antibodies as well as methods for detection of Gla in biological fluids, tissue extracts, tissue specimens, in which methods said antibodies are used, are also described. There is also described the use of said antibodies for immunopurification of Gla-containing proteins or peptides by, for instance, immunoprecipitation or immunoaffinity chromatography.Type: GrantFiled: March 1, 2001Date of Patent: October 21, 2008Assignee: Protease ABInventors: Johan Stenflo, Loisa Mary Stenberg, Mark Alan Brown
-
Publication number: 20080234311Abstract: The present invention provides a method for the detection and quantification of A?1-40 produced in native cell types and tissues. Also provided are assays and kits to determine the effect of compounds on the production of amyloid ? peptides.Type: ApplicationFiled: November 19, 2007Publication date: September 25, 2008Inventors: Jinhe Li, Murali Gopalakrishnan
-
Publication number: 20080220540Abstract: The method for developing an antibody that exclusively binds to csPCNA.Type: ApplicationFiled: November 13, 2007Publication date: September 11, 2008Inventors: Linda H. Malkas, Robert J. Hickey, Pamela E. Bechtel, Min Park, Derek J. Hoelz, Dragana Tomic, Lauren Schnaper
-
Patent number: 7410768Abstract: A method and test device for differentiating between states of an analyte that can exist in different forms, such as follicle stimulating hormone (FSH). The method or test device uses a pair of specific binding agents, especially monoclonal antibodies, in two assays for the same analyte. The assays, applied to contemporaneous samples, differ from one another in format, one being a two step assay and the other being one step. A novel pair of anti-FSH monoclonal antibodies that can be used together in two such assays to differentiate pre-menopausal and post-menopausal FSH samples is disclosed.Type: GrantFiled: April 3, 2001Date of Patent: August 12, 2008Assignee: Inverness Medical Switzerland GmbHInventors: Lorraine D. Butlin, John Coley, Stephen J. Eida, Mohamed M. Gani
-
Patent number: 7410771Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.Type: GrantFiled: April 14, 2006Date of Patent: August 12, 2008Assignee: The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock
-
Patent number: 7399636Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: December 31, 2002Date of Patent: July 15, 2008Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7399644Abstract: An assay method for determining presence of a target antibody or antigen in a specimen qualitatively or quantitatively by mixing the specimen with an antigen or antibody immunologically reactive with the target antibody or antigen, and assaying the level of the immunological agglutination reaction, wherein the reactive antigen or antibody is effectively immobilized on the carrier via an amino acid sequence capable of binding to the carrier.Type: GrantFiled: June 4, 2003Date of Patent: July 15, 2008Assignee: Canon Kabushiki KaishaInventors: Tsutomu Honma, Tetsuya Yano, Tsuyoshi Nomoto, Shinya Kozaki
-
Publication number: 20080160002Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.Type: ApplicationFiled: October 29, 2007Publication date: July 3, 2008Inventors: Tetsuya Gatanaga, Gale A. Granger
-
Patent number: 7390489Abstract: The present invention relates to a monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria monocytogenes using the monoclonal antibody. The inventive monoclonal selectively recognizes only Listeria monocytogenes, so that the use of such an antibody allows for rapid determination of the food contamination with these bacteria pathogenic to humans.Type: GrantFiled: October 8, 2004Date of Patent: June 24, 2008Assignee: Komed Co., Ltd.Inventors: Byung Soo Youn, Young Soo Yang, Nam Seok Lee, Kang Yeol Yu, Young Soon Noh, Hong Je Park, Moon Yeon Youn, Min Sup Chung, Sung Shik Min, Jae Jun Jeong
-
Publication number: 20080145872Abstract: The present invention is directed to a composition that includes a functionally active, individual HLA trimolecular complex expressed on the surface of an immortalized, non-human cell line. Methods of obtaining high expression of the transferred HLA molecule, as well as assays that utilize such recombinant cell line as a platform, are also disclosed. Methods of purifying HLA from such recombinant cell line and methods of using the purified HLA to detect or remove anti-HLA antibodies are also disclosed.Type: ApplicationFiled: January 17, 2008Publication date: June 19, 2008Inventor: William H. Hildebrand
-
Patent number: 7385040Abstract: The present invention relates to a method of separating antibodies from contaminants in a solution, which method comprises contacting the solution with a chromatography resin comprised of a support to which multi-modal ligands have been immobilised, wherein a multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system. In one embodiment, the ring-forming atoms of the aromatic or hereoaromatic entity are selected among C, S or O, and the cation exchanging group is a weak cation exchanger. The present method may be used as a single step procedure or as a polishing step following a capture on a Protein A column.Type: GrantFiled: February 24, 2005Date of Patent: June 10, 2008Assignee: GE Healthcare Bio-Sciences ABInventors: Bo-Lennart Johansson, Hans J. Johansson, Anders Ljunglöf, Jean-Luc Maloisel, Nicolas Thevenin
-
Patent number: 7378250Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: May 7, 2007Date of Patent: May 27, 2008Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Desire Jose Collen
-
Publication number: 20080115244Abstract: The immunoglobulins of the present invention are useful therapeutic immunoglobulins against mucosal pathogens such as S. mutans. The immunoglobulins contain a protection protein that protects the immunoglobulins in the mucosal environment. The invention also includes the greatly improved method of producing immunoglobulins in plants by producing the protection protein in the same cell as the other components of the immunoglobulins. The components of the immunoglobulin are assembled at a much improved efficiency. The method of the invention allows the assembly and high efficiency production of such complex molecules. The invention also contemplates the production of immunoglobulins containing protection proteins in a variety of cells, including plant cells, that can be selected for useful additional properties. The use of immunoglobulins containing protection proteins as therapeutic antibodies against mucosal and other pathogens is also contemplated.Type: ApplicationFiled: November 28, 2006Publication date: May 15, 2008Applicant: The Regents of University of CaliforniaInventors: Andrew C. Hiatt, Julian K.-C. Ma, Thomas Lehner
-
Publication number: 20080108147Abstract: Methods and compositions are disclosed for reducing non-specific binding in a binding assay for the determination of an analyte in a sample wherein one of the reagents for conducting the binding assay is an antibody reagent. The methods comprise treating the antibody reagent at a pH of about 2.0 to about 3.5. The method may further comprise treating the antibody reagent with a reducing agent in an amount sufficient to reduce non-specific binding of the antibody reagent. In some embodiments the reducing agent may be a thiol-containing reducing agent or a combination of two or more thiol-containing reducing agents.Type: ApplicationFiled: November 3, 2006Publication date: May 8, 2008Inventors: Tie Wei, Pratap Singh, James Duffy, Amy Posey
-
Publication number: 20080107673Abstract: An active, or passive vaccine utilizing purified non-toxic mutant TcdB toxins from Clostridium difficile for humans and animals against infections caused by C. difficile and/or C. sordellii. Persons most potentially affected by C. difficile infections include hospitalized patients, infants, and elderly persons. The TcdB toxin mutant of the vaccine preferably lacks the toxicity of a native C. difficile TcdB toxin. A serum comprising antibodies raised to the TcdB toxin mutant is also available for treating humans or animals against C. difficile infections. The serum may be used in a method for conferring passive immunity against C. difficile. Antibodies to the TcdB toxin mutant may be used in diagnostic tests or in treatments to clear TcdB toxin from bodily fluids. The mutant TcdB toxin may be produced by recombinant methods using cDNA encoding the toxin, the cDNA contained for example in a plasmid or host cell.Type: ApplicationFiled: June 4, 2007Publication date: May 8, 2008Inventors: Jimmy D. Ballard, Lea M. Spyres
-
Patent number: 7358053Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.Type: GrantFiled: June 6, 2003Date of Patent: April 15, 2008Assignee: McGill UniveristyInventors: Roger K. Prichard, Ming Xu, Ana Paula Ribeiro, William J. Blackhall, Robin N. Beech, Marcelo Molento, Hao Yuan Liu
-
Patent number: 7351686Abstract: A vaccine for reducing disease progression, and/or protection of motor nerve degeneration, and/or protection from glutamate toxicity in motor neurone disease (MND), particularly amyotrophic lateral sclerosis (ALS), patients, comprising an active agent selected from the group consisting of Cop 1, a Cop 1-related peptide, a Cop 1-related polypeptide, and poly-Glu, Tyr. The active agent is preferably Cop 1 or poly-Glu, Tyr, and can be administered with or without an adjuvant.Type: GrantFiled: December 5, 2002Date of Patent: April 1, 2008Assignee: Yeda Research and Development Co. Ltd.Inventors: Michal Eisenbach-Schwartz, Esther Yoles, Jonathan Kipnis
-
Patent number: 7348010Abstract: The present invention relates to peptides of the extracellular domain of a HER-2/neu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2/neu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2/neu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2/neu in a subject in need thereof.Type: GrantFiled: February 27, 2002Date of Patent: March 25, 2008Inventors: Christoph Zielinski, Otto Scheiner, Erika Jensen-Jarolim, Heimo Breiteneder, Hubert Pehamberger
-
Patent number: 7342091Abstract: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.Type: GrantFiled: December 21, 2001Date of Patent: March 11, 2008Assignee: Fraunhofer-Gesellschaf zur Forderung der angewandten Forschung e.VInventors: Afroditi Kapurniotu, Jürgen Bernhagen, Herwig Brunner
-
Patent number: 7335516Abstract: A method of improving specific immune responses to small immunogens, haptens, has been developed by changing the linkage between the hapten and carrier being used for immunization. Antibodies to a glycated protein have been developed, utilizing an immunogen which is composed of a glycated peptide mimic of the glycated peptide sequence which is the target epitope, wherein the peptide mimic is constructed to conformationally mimic the conformation of the peptide in the native protein, the peptide mimic contains no charged groups or other immunodominant group, and the peptide mimic is connected to a spacer sequence equivalent to a peptide spacer of between one and thirty amino acids in length, which serves to position the peptide epitope in a conformation that approximates its conformation in the native protein. In a further embodiment the peptide mimic and spacer are linked to a carrier molecule.Type: GrantFiled: August 21, 2002Date of Patent: February 26, 2008Assignee: Serex, Inc.Inventors: Judith Fitzpatrick, Regina Lenda
-
Patent number: 7329542Abstract: This invention relates to the diagnosis of cancer, and in particular to the identification and detection of cancer-specific antigens, the invention provides antibody probes and methods for using the probes for detection and purification of cancer-specific antigens, and in the preparation of vaccine compositions. Antibodies against cancer-specific antigens are also disclosed and claimed.Type: GrantFiled: November 29, 2001Date of Patent: February 12, 2008Assignee: Cancerprobe Pty Ltd.Inventors: Alex Lopata, Elza Meeusen, Nunzio Mancuso
-
Patent number: 7312057Abstract: Hydrophobic polymer surfaces whose level of protein binding is less than about 50-80 ng/cm2 are achieved by: (1) applying a coating solution composed of a solvent and a non-ionic surfactant having a HLB number of less than 5 to the surface; and (2) drying the surface to remove the solvent and thereby bring the surfactant into direct contact with the hydrophobic polymer. The combination of a low HLB number and the drying step have been found to produce low binding surfaces which can withstand multiple washes with water and/or protein-containing solutions Alternatively, the low binding surfaces can be produced by applying the non-ionic surfactant to the mold surfaces which contact molten polymer and form the polymer into a desired shape, e.g., into a multi-well plate, a pipette tip, or the like. Further, the low binding surfaces may be produced by incorporating non-soluble, non-ionic surfactants having an HLB number of less than or equal to 10 into a polymer blend prior to molding the article.Type: GrantFiled: March 3, 2003Date of Patent: December 25, 2007Assignee: Corning IncorporatedInventors: Dana Craig Bookbinder, Edward John Fewkes, Jr., James Arthur Griffin, Frances M. Smith, David L. Tennent
-
Patent number: 7294481Abstract: A method for producing recombinant proteins, preferably fusion proteins comprising an Fc portion of an immunoglobulin molecule, more preferably fusion proteins comprising an extracellular domain of a tumor necrosis factor receptor fused to the Fc portion of an immunoglobulin molecule, is disclosed. The method of the present invention allows a reduction of misfolding of the protein, thereby giving rise to a higher yield of the desired protein.Type: GrantFiled: August 30, 2002Date of Patent: November 13, 2007Inventor: Victor P. Fung
-
Patent number: 7270816Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: October 27, 2003Date of Patent: September 18, 2007Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7262018Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.Type: GrantFiled: September 14, 2004Date of Patent: August 28, 2007Assignee: National Institutes of HealthInventors: Harry V. Gelboin, Kristopher W. Krausz, Frank J. Gonzalez
-
Patent number: 7259022Abstract: A method is provided for producing motif-specific, context-independent antibodies which recognize a plurality of peptides or proteins within a genome that contain the same motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino adds flanking the motif. Motif-specific, context-independent antibodies produced by the disclosed method are also provided. The method encompasses motifs consisting of a single modified amino acid, as well as short motifs comprising multiple invariant amino acids including one or more modified amino acids, such as all or part of kinase consensus substrate motifs, protein-protein binding motifs, or other cell signaling motifs. Methods of using the antibodies, e.g. for genome-wide profiling, are also provided.Type: GrantFiled: November 13, 2001Date of Patent: August 21, 2007Assignee: Cell Signaling Technology, Inc.Inventors: Michael J. Comb, Yi Tan, Hui Zhang
-
Patent number: 7253265Abstract: An antibody and a method for producing an antibody that specifically binds to a full length amino acid sequence of human Delta-1.Type: GrantFiled: January 27, 2005Date of Patent: August 7, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Seiji Sakano, Akira Itoh
-
Patent number: 7252929Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.Type: GrantFiled: November 3, 2003Date of Patent: August 7, 2007Assignee: United States of America, as represented by the Secretary, Dept of Health & Human ServicesInventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
-
Patent number: 7244580Abstract: The present invention relates to identification of polypeptides useful for generating antibodies specific for non-human IgE, particularly equine IgE. The invention, therefore, also relates to antibodies that specifically bind to IgE and methods to detect IgE using the antibodies. The invention also provides a kit for detection of IgE.Type: GrantFiled: November 8, 2001Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: Laurel J. Gershwin, Howard David Pettigrew, Warren V. Kalina
-
Patent number: 7238488Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.Type: GrantFiled: September 13, 2002Date of Patent: July 3, 2007Inventors: Grace Maresh, Alan D. Snow
-
Patent number: 7229776Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: March 17, 2004Date of Patent: June 12, 2007Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 7230086Abstract: The invention is a method of identifying the presence of a disease state in a mammal which is associated with degradation of connective tissue in the mammal which contains the protein known as YKL-40. The method is a competitive immunoassay for YKL-40. It can be used, for example, to identify the presence of inflammatory or degenerative joint disease and tumor metastasis (to the extent it can be correlated to serum YKL-40 levels). Serum YKL-40 levels as detected and quantified by the inventive method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers.Type: GrantFiled: August 25, 2003Date of Patent: June 12, 2007Assignee: The Regents of the University of CaliforniaInventors: Paul A. Price, Julia S. Johansen
-
Patent number: 7220838Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G?CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: GrantFiled: June 11, 2003Date of Patent: May 22, 2007Assignee: The Johns Hopkins University School of MedicineInventors: Philip A. Beachy, Jeffrey A. Porter
-
Patent number: 7220559Abstract: This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.Type: GrantFiled: January 23, 2001Date of Patent: May 22, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventor: Ilya Trakht
-
Patent number: 7198954Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: August 1, 2000Date of Patent: April 3, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7195926Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.Type: GrantFiled: March 8, 2000Date of Patent: March 27, 2007Assignee: Incyte CorporationInventors: Roger Coleman, Scott Michael Braxton, Jeffrey J. Seilhamer
-
Patent number: 7163798Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSc is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.Type: GrantFiled: March 3, 2006Date of Patent: January 16, 2007Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Patent number: 7153661Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.Type: GrantFiled: July 3, 2002Date of Patent: December 26, 2006Assignee: Research Corporation Technologies, Inc.Inventor: Shohei Koide
-
Patent number: 7151166Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: February 27, 2004Date of Patent: December 19, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman
-
Patent number: 7138241Abstract: The present invention provides for a method of selecting an antibody against a target substance to be measured, which comprises selecting the antibody against the target substance by antigen-antibody reaction in the presence of a substance interfering with the antigen-antibody reaction. That is, an antigen and a labeled antigen are reacted with the antibody in the presence of an interfering substance, such as an environment pollutant, and on the basis of the degree of reaction thereof, the antibody against the target substance, which is highly resistant to the interfering substance, is selected. Thereby, even if a test sample is contaminated with a substance interfering with antigen-antibody reaction, the antibody, which is highly resistant to the substance interfering with antigen-antibody reaction, is not influenced by the interfering substance and gives a correct value in the quantification.Type: GrantFiled: May 17, 2002Date of Patent: November 21, 2006Assignee: Japan Envirochemicals, Ltd.Inventors: Yasuhiro Goda, Ayako Kobayashi, Masato Hirobe
-
Patent number: 7138247Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.Type: GrantFiled: March 25, 2005Date of Patent: November 21, 2006Assignee: Stressgen Biotechnologies CorporationInventors: Heather A. Boux, Geraldine S. Wong, Henry Rodriguez
-
Patent number: 7118924Abstract: An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents.Type: GrantFiled: February 21, 2001Date of Patent: October 10, 2006Assignee: Biogen IDEC Inc.Inventors: Marco Anthony Coccia, Peter Brams
-
Patent number: 7087725Abstract: The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.Type: GrantFiled: October 29, 2004Date of Patent: August 8, 2006Assignees: The Faculty of Medicine of the University of Geneva, Biogen Idec MA Inc.Inventors: Jeffrey Browning, Yves Chicheportiche
-
Patent number: 7087213Abstract: A method of isolating and detecting the presence of a disease related conformation of a protein (e.g., PrPSc) is disclosed. The sample is treated such as by contacting it with a protease and then contacting the treated sample with a binding partner which binds the PrPSc which can be isolated and separated from the sample.Type: GrantFiled: February 8, 2005Date of Patent: August 8, 2006Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar